Congo Virus (CCHF) PCR Qualitative at Chughtai Lab

Congo Virus (CCHF) PCR Qualitative at Chughtai Lab

Crimean-Congo Hemorrhagic Fever (CCHF), commonly referred to as Congo Virus, is a severe, highly infectious zoonotic disease caused by an RNA virus of the Bunyaviridae family (genus Nairovirus). With a high mortality rate ranging from 10% to 40%, rapid and highly accurate diagnosis is critical for patient survival, clinical management, and public health safety. The Congo Virus (CCHF) PCR Qualitative test at Chughtai Lab is a state-of-the-art molecular diagnostic assay designed to detect the presence of CCHF viral RNA in human blood during the acute phase of infection. By utilizing Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) technology, this test offers unmatched sensitivity and specificity, allowing healthcare providers to confirm or rule out the infection in its earliest stages when clinical symptoms are often non-specific.

The CCHF virus is primarily transmitted to humans through the bites of infected Hyalomma ticks or through direct contact with the blood, secretions, or tissues of infected livestock such as cattle, sheep, and goats. In Pakistan, CCHF is endemic, with seasonal surges frequently observed, particularly around religious festivals like Eid-ul-Adha due to increased animal handling and transport. Because the early symptoms of Congo Virus closely mimic other endemic tropical diseases like Dengue fever, Malaria, and Typhoid, clinical diagnosis alone is highly unreliable. The Congo Virus (CCHF) PCR Qualitative test serves as the definitive gold standard diagnostic tool, enabling targeted clinical intervention, the administration of supportive care, and the immediate implementation of strict isolation protocols to prevent nosocomial outbreaks in healthcare settings.

The molecular diagnostic process at Chughtai Lab involves extracting viral RNA from the patient’s blood sample, followed by reverse transcription into complementary DNA (cDNA) and subsequent amplification using highly specific primers and probes targeting conserved regions of the CCHF viral genome. This qualitative assay provides a clear “Detected” or “Not Detected” result, indicating the presence or absence of active viral replication. The clinical value of this test is immense, as it detects the virus before the patient’s immune system produces detectable antibodies, making it the most reliable diagnostic method during the first seven to nine days of symptom onset.

Clinical Procedure: What to Expect

Patient Preparation

Proper patient preparation and adherence to safety guidelines are essential for ensuring accurate results and protecting healthcare workers during sample collection for suspected CCHF cases. Patients and referring clinicians should observe the following guidelines:

• No Dietary Restrictions: There is no requirement for fasting before the Congo Virus (CCHF) PCR Qualitative test. The patient can eat and drink normally prior to sample collection.
• Disclose Clinical History: It is vital to inform the laboratory staff and phlebotomist if the patient has had recent exposure to livestock, tick bites, travel to endemic areas, or contact with a confirmed CCHF patient.
• Medication History: Patients must disclose any ongoing medications, particularly anticoagulants (blood thinners) like aspirin, warfarin, or heparin, as CCHF causes severe thrombocytopenia and prolonged bleeding times, requiring extra care during venipuncture.
• Strict Infection Control: Due to the highly infectious nature of the Congo Virus through blood and bodily fluids, suspected patients should ideally be isolated, and sample collection should be performed using stringent personal protective equipment (PPE) by trained personnel.

During the Procedure

The sample collection process is conducted with the highest level of biosafety and clinical precision to ensure sample integrity and prevent cross-contamination or accidental exposure:

• Aseptic Venipuncture: A trained phlebotomist wearing full personal protective equipment (PPE), including an N95 mask, double gloves, protective gown, and eye protection, will perform the venipuncture.
• Sample Collection Tube: Approximately 3 to 5 mL of venous blood is drawn from a vein in the arm, typically collected in an EDTA (purple top) tube or a serum separator tube (SST), depending on specific laboratory protocols.
• Hemostasis and Pressure: Due to the risk of bleeding disorders associated with CCHF, firm pressure must be applied to the puncture site for an extended period after needle removal to ensure complete hemostasis and prevent hematoma formation.
• Triple Packaging System: The collected blood sample is immediately labeled with the patient’s details and placed in a specialized biohazard triple-packaging system to ensure safe transport to the molecular biology laboratory at Chughtai Lab, preventing any risk of leakage or exposure during transit.
• Laboratory Processing: In the molecular diagnostics department, automated extraction systems isolate the viral RNA, which is then subjected to real-time RT-PCR amplification using advanced thermocyclers under strict Biosafety Level 3 (BSL-3) equivalent precautions.

When is a Congo Virus (CCHF) PCR Qualitative Test Performed?

1. History of Tick Bites or Direct Animal Exposure

Physicians routinely order the Congo Virus (CCHF) PCR Qualitative test when a patient presents with acute febrile symptoms and has a documented history of a tick bite or close physical contact with livestock. This is particularly common among shepherds, slaughterhouse workers, veterinarians, and individuals visiting animal markets in endemic regions. Early molecular testing is crucial in these high-risk individuals to confirm the diagnosis before severe hemorrhagic manifestations develop.

2. Presentation of Acute Hemorrhagic Symptoms

The onset of hemorrhagic signs, such as petechiae (tiny red spots on the skin), ecchymosis (bruising), epistaxis (nosebleeds), hematemesis (vomiting blood), or melena (dark, tarry stools), in a febrile patient is a critical clinical indication for this test. When these symptoms appear, the viral load in the blood is typically high, making qualitative RT-PCR highly effective in confirming CCHF as the underlying cause of the hemorrhagic syndrome, allowing for immediate intensive supportive therapy.

3. High-Risk Occupational Screening and Post-Exposure Monitoring

Healthcare professionals, laboratory technicians, and nursing staff who have been accidentally exposed to the blood or bodily fluids of a suspected or confirmed CCHF patient require immediate monitoring. If they develop any early symptoms, such as sudden fever, myalgia, or headache, the qualitative PCR test is performed immediately to detect early-stage viremia, enabling prompt treatment with ribavirin and the enforcement of quarantine measures.

4. Differential Diagnosis of Acute Undifferentiated Fevers

In regions where multiple vector-borne and infectious diseases coexist, patients presenting with sudden onset of high fever, severe headache, backache, joint pain, abdominal pain, and vomiting pose a diagnostic challenge. Clinicians request the Congo Virus PCR test alongside Dengue, Malaria, and Typhoid panels to rule out CCHF, ensuring that patients receive the correct treatment and are not subjected to inappropriate therapies that could worsen bleeding tendencies.

5. Monitoring and Infection Control in Suspected Outbreaks

During localized outbreaks or seasonal surges of hemorrhagic fever, public health authorities and hospital epidemiologists utilize the qualitative PCR test to screen suspected cases admitted to isolation wards. Rapid confirmation of positive cases helps map the outbreak, implement vector control measures, and allocate medical resources effectively to contain the spread of this highly lethal virus.

What Does a Congo Virus (CCHF) PCR Qualitative Test Detect?

The Congo Virus (CCHF) PCR Qualitative test is designed to identify specific molecular targets and clinical indicators associated with the active replication of the Crimean-Congo Hemorrhagic Fever virus. The test detects and confirms:

• Presence of CCHF viral genomic RNA in the patient’s blood.
• Active, ongoing systemic viral replication (viremia).
• Acute phase of Crimean-Congo Hemorrhagic Fever, typically within the first 1 to 9 days of infection.
• The specific etiology of sudden-onset high fever in high-risk patients.
• The underlying cause of severe thrombocytopenia and leukopenia in suspected hemorrhagic cases.
• Infection transmitted via the bite of an infected Hyalomma tick.
• Zoonotic transmission from direct contact with infected animal blood or tissues.
• Nosocomial (hospital-acquired) transmission in exposed healthcare workers.
• Molecular confirmation of infection prior to the development of detectable IgM or IgG antibodies.
• The primary cause of unexplained petechiae, ecchymosis, and mucosal bleeding.
• Etiology of severe myalgia, arthralgia, and lumbar back pain in endemic regions.
• The cause of acute hepatocellular damage associated with elevated liver enzymes in hemorrhagic patients.
• The presence of viral genetic material in patients presenting with altered mental status or encephalopathy during late-stage CCHF.
• Validation of clinical suspicion in patients with prolonged prothrombin time (PT) and activated partial thromboplastin time (aPTT).
• Confirmation of CCHF in patients presenting with severe gastrointestinal symptoms like hematemesis or melena.
• Etiology of multi-organ dysfunction syndrome (MODS) in critically ill febrile patients.
• The presence of viral RNA in post-exposure febrile contacts of confirmed cases.
• Rule-out of CCHF in patients presenting with non-viremic, unrelated febrile illnesses.
• The molecular basis for immediate clinical isolation and initiation of experimental antiviral therapy (e.g., Ribavirin).
• Definitive laboratory evidence required for public health reporting and epidemiological tracking.

Turnaround Time and Report Access at Chughtai Lab

Chughtai Lab understands the critical and life-threatening nature of a suspected Congo Virus infection. Consequently, the laboratory prioritizes molecular testing for CCHF to ensure rapid clinical decision-making. The turnaround time (TAT) for the Congo Virus (CCHF) PCR Qualitative test is typically within 24 to 48 hours from the time the sample reaches the central molecular reference laboratory. This timeline is necessary to maintain the highest standards of biosafety, sample preparation, RNA extraction, and real-time PCR amplification.

Reports are reviewed and signed off by qualified consultant pathologists and molecular biologists. Chughtai Lab offers seamless digital access to test results. Patients and healthcare providers receive an automated SMS notification as soon as the report is finalized. Reports can be viewed, downloaded, and printed online through the official Chughtai Lab website portal or via the user-friendly Chughtai Lab Mobile App. Physical copies of the reports can also be collected from any of the numerous Chughtai Lab collection centers located across Pakistan.

Congo Virus (CCHF) PCR Qualitative Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
CCHF Viral RNA	Not Detected (Negative)	Detected (Positive) – Indicates active CCHF viral infection.
Internal Control (IC)	Detected / Valid	Not Detected / Invalid – Indicates PCR inhibition or extraction failure; requires retesting.
Cycle Threshold (Ct) Value	No Ct value observed (flatline)	Low Ct value (high viral load) or High Ct value (low viral load/early or resolving infection).
Platelet Count (Associated)	150,000 – 450,000 /µL	Severe Thrombocytopenia (<50,000 /µL) – Common in active CCHF.
White Blood Cell Count (Associated)	4,000 – 11,000 /µL	Leukopenia or Leukocytosis – Reflects systemic viral response.
Coagulation Profile (PT/aPTT)	Within normal reference ranges	Prolonged PT and aPTT – Indicates severe coagulopathy and risk of bleeding.
Liver Enzymes (ALT/AST)	Within normal reference ranges	Markedly elevated ALT and AST – Indicates acute hepatic involvement.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Congo Virus (CCHF) PCR Qualitative?

• State-of-the-Art Molecular Diagnostics: Chughtai Lab utilizes advanced real-time PCR technology, ensuring maximum sensitivity and specificity for detecting CCHF viral RNA.
• Strict Biosafety Standards: Samples are processed under rigorous Biosafety Level 3 (BSL-3) equivalent protocols to ensure the safety of laboratory staff and prevent cross-contamination.
• Expert Pathologists and Scientists: The molecular biology department is led by highly qualified consultant pathologists and molecular biologists with extensive experience in infectious disease diagnostics.
• Rapid Turnaround Time: Recognizing the emergency nature of CCHF, Chughtai Lab prioritizes these samples to deliver accurate results as quickly as possible.
• Convenient Digital Access: Patients can easily access, download, and share their reports online via the Chughtai Lab website or mobile application.
• Extensive Network: With hundreds of collection centers across Pakistan, patients can access high-quality diagnostic services close to home.
• Home Sample Collection: Chughtai Lab offers specialized home sample collection services with trained phlebotomists equipped with appropriate safety gear.
• ISO 15189 Certified Processes: Chughtai Lab adheres to international quality management standards, ensuring reliable, reproducible, and clinically accurate test results.